

Stacey C Tobin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7982731/publications.pdf>

Version: 2024-02-01

15
papers

54
citations

2257833

3
h-index

1719901

7
g-index

15
all docs

15
docs citations

15
times ranked

125
citing authors

#	ARTICLE	IF	CITATIONS
1	Generating pluripotent stem cells: Differential epigenetic changes during cellular reprogramming. <i>FEBS Letters</i> , 2012, 586, 2874-2881.	1.3	32
2	U=U gains strength with release of PARTNER2 data. <i>Aids</i> , 2019, 33, N1.	1.0	7
3	VOICE reveals the need to improve adherence in PrEP trials. <i>Aids</i> , 2015, 29, N9.	1.0	5
4	A brief historical overview of artificial intelligence research. <i>Information Services and Use</i> , 2020, 39, 291-296.	0.1	3
5	Atypical symptoms of acute retroviral syndrome seen in one-third of patients with primary HIV infection. <i>Aids</i> , 2015, 29, N15.	1.0	2
6	Cumulative antiretroviral therapy exposure increases annual incidence of chronic kidney disease in a large international cohort study. <i>Aids</i> , 2016, 30, N16.	1.0	2
7	Confirmation of Parthenogenetic Identity by Recombination Signature in Human Embryonic Stem Cells. <i>Stem Cells and Development</i> , 2013, 22, 1016-1017.	1.1	1
8	Recent advances in CRISPR/Cas9 technology for targeting latent HIV-1 reservoirs. <i>Aids</i> , 2016, 30, N17.	1.0	1
9	A setback for kick and kill?. <i>Aids</i> , 2019, 33, N6.	1.0	1
10	Population-based analysis of HIV-1 antibodies reveals structural constraints that may inform vaccine design. <i>Aids</i> , 2015, 29, N13.	1.0	0
11	Updated European paediatric guidelines focus on long-term health consequences of HIV-1 infection and treatment. <i>Aids</i> , 2015, 29, N5.	1.0	0
12	CD8+ T-memory stem cells maintain the capacity for a cellular immune response against HIV-1 in patients on suppressive antiretroviral therapy. <i>Aids</i> , 2015, 29, N11.	1.0	0
13	Protecting the mucosal immune response in treatment-naïve HIV-infected patients. <i>Aids</i> , 2016, 30, N15.	1.0	0
14	Evaluating the generalizability of clinical trials of direct-acting antivirals for HIV–hepatitis C virus coinfection. <i>Aids</i> , 2017, 31, N11-N12.	1.0	0
15	Preexposure prophylaxis use continues to evolve. <i>Aids</i> , 2019, 33, N5.	1.0	0